Moderna vs Pfizer Which Is More Profitable?

Moderna and Pfizer are two pharmaceutical companies at the forefront of developing COVID-19 vaccines. Their stocks have been highly sought after by investors looking to capitalize on the success of their respective vaccines. Moderna's stock has seen significant gains due to the effectiveness of its vaccine and potential for future growth. On the other hand, Pfizer's stock has also performed well, bolstered by its strong financials and established presence in the pharmaceutical industry. Investors are closely monitoring these two stocks to assess their long-term potential in a post-pandemic world.

Moderna or Pfizer?

When comparing Moderna and Pfizer, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between Moderna and Pfizer.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. Moderna has a dividend yield of -%, while Pfizer has a dividend yield of 6.4%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. Moderna reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%. On the other hand, Pfizer reports a 5-year dividend growth of 4.08% year and a payout ratio of 221.76%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with Moderna P/E ratio at -7.40 and Pfizer's P/E ratio at 34.91. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. Moderna P/B ratio is 1.38 while Pfizer's P/B ratio is 1.61.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, Moderna has seen a 5-year revenue growth of 10.71%, while Pfizer's is 0.13%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with Moderna's ROE at -17.68% and Pfizer's ROE at 4.72%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $42.26 for Moderna and $26.22 for Pfizer. Over the past year, Moderna's prices ranged from $42.26 to $170.47, with a yearly change of 303.38%. Pfizer's prices fluctuated between $25.20 and $31.54, with a yearly change of 25.16%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.